Clinical trial · Observational
BostonGene-Integrated Genomic Registry (BIGR)
BostonGene-Integrated Genomic Registry Study
NCT04991922CI-TRIAL-00073781recruitingClinicalTrials.gov clinicaltrialsProvenance
- Source
- ClinicalTrials.gov
- Retrieved
- Sep 8, 2026
- Layer
- normalized (units and labels harmonized; values unchanged)
- Run
- ING-CLINICALTRIALS-20260908-000001
Summary
Brief summary (as posted)
The purpose of this project is to develop a comprehensive database of genomic, transcriptomic, molecular, and clinical characteristics of oncology patients to discover, define, and develop genomic and transcriptomic markers to improve future clinical outcomes across cancer types
Conditions
Conditions (1)
Free-text conditions as registered, with the CancerIndex entity they were reconciled to and the match type.
| Condition (as posted) | Mapped entity | Match | Confidence |
|---|---|---|---|
| Malignancy | Malignant Neoplasm | ALIAS | 0.90 |
Interventions
Interventions (0)
Data not yet available
No intervention recorded.
Design
Arms and outcomes
Arms (0)
[]Primary outcomes (1)
- measure
- association between major finding and outcome, Descriptive
- timeFrame
- 5 years
- description
- associations between genomic findings and outcomes of cancer patients who have undergone comprehensive sequencing.
Secondary outcomes (2)
- measure
- Predictive probability
- timeFrame
- 5 years
- description
- identify molecular findings associated with therapy.
- measure
- Clinical trials matching
- timeFrame
- 5 years
- description
- identify and link registry subjects to future molecular-based clinical research
Eligibility
Eligibility (as posted)
- Sex
- All
- Minimum age
- 18 Years
Show eligibility criteria text
Inclusion Criteria: 1. Suspected or confirmed malignancy 2. Planned comprehensive genomic (\> 100 genes) and/or molecular analysis; or genomic and/or molecular data available from prior sequencing 3. Baseline demographics and treatment information available 4. Willingness for future contact by BIRG study personnel to provide information regarding associated cancer outcomes and treatment. 5. Signed informed consent to participate in the study. 6. Living in the United States at the time of enrollment Exclusion Criteria: Life expectancy \< 3 months
References
Publications (3)
- BACKGROUNDMurciano-Goroff YR, Warner AB, Wolchok JD. The future of cancer immunotherapy: microenvironment-targeting combinations. Cell Res. 2020 Jun;30(6):507-519. doi: 10.1038/s41422-020-0337-2. Epub 2020 May 28. PMID 32467593
- BACKGROUNDSambi M, Bagheri L, Szewczuk MR. Current Challenges in Cancer Immunotherapy: Multimodal Approaches to Improve Efficacy and Patient Response Rates. J Oncol. 2019 Feb 28;2019:4508794. doi: 10.1155/2019/4508794. eCollection 2019. PMID 30941175
- BACKGROUNDOlivier M, Asmis R, Hawkins GA, Howard TD, Cox LA. The Need for Multi-Omics Biomarker Signatures in Precision Medicine. Int J Mol Sci. 2019 Sep 26;20(19):4781. doi: 10.3390/ijms20194781. PMID 31561483